Key Points
- Insider sale: Damien Alan Perriman sold 3,729 eXoZymes shares for $19,428.09, reducing his ownership by 11.5%; the sale covered tax withholding tied to vested equity awards.
- Weak financial performance: eXoZymes reported a quarterly loss of $0.33 per share, with analysts expecting a full-year loss of $1.19 per share.
- Stock outlook remains negative: EXOZ opened at $3.75, near its 52-week low of $3.70, and analysts’ consensus rating is “Reduce,” despite Zacks upgrading the stock to “Hold.”
eXoZymes Inc. (NASDAQ:EXOZ - Get Free Report) insider Damien Alan Perriman sold 3,729 shares of eXoZymes stock in a transaction on Monday, October 12th. The shares were sold at an average price of $5.21, for a total value of $19,428.09. Following the transaction, the insider directly owned 28,692 shares of the company's stock, valued at approximately $149,485.32. The trade was a 11.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
eXoZymes Price Performance
Shares of EXOZ stock opened at $3.75 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.81 and a current ratio of 3.81. The stock has a market capitalization of $34.89 million, a PE ratio of -3.15 and a beta of 3.19. eXoZymes Inc. has a 52 week low of $3.70 and a 52 week high of $18.40. The stock's fifty day moving average is $5.94 and its 200-day moving average is $7.93.
eXoZymes (NASDAQ:EXOZ - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.33) earnings per share (EPS) for the quarter. Equities research analysts expect that eXoZymes Inc. will post -1.19 EPS for the current fiscal year.
Institutional Investors Weigh In On eXoZymes
A hedge fund recently bought a new stake in eXoZymes stock. BlackRock Inc. purchased a new position in shares of eXoZymes Inc. (NASDAQ:EXOZ - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 9,610 shares of the company's stock, valued at approximately $81,000. BlackRock Inc. owned approximately 0.10% of eXoZymes at the end of the most recent reporting period.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on EXOZ shares. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of eXoZymes in a research note on Wednesday, August 26th. Zacks Research upgraded eXoZymes to a "hold" rating in a research note on Friday, October 2nd. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Reduce".
View Our Latest Stock Report on EXOZ
eXoZymes Company Profile
(
Get Free Report)
eXoZymes, Inc is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
